Xarelto Bellwether Trial Rescheduled
The first Xarelto bellwether trial was originally expected to commence next month before US District Judge Eldon Fallon in US District Court of Eastern District of Louisiana. This would have been an important step since bleeding cases tied to this blood-thinner are around 14,000. However, both parties agreed to reschedule this monumental avenue of justice
Read More
Johnson & Johnson Bribed Doctors to Push Xarelto
New disconcerting information concerning the deadly blood thinner, Xarelto has made headlines. This time it doesn’t involve the faulty Rocket AF clinical trial, which was responsible for Xarelto’s approval, or about the malfunction of the device used in that faulty trial. This is about payoffs. Journalists at ProPublica uncovered Johnson & Johnson’s spending budget on
Read More
The Michael Brady Lynch Firm on the Forefront of Eliquis Litigation
On January 26 in Miami, Florida, the US Judicial Panel on Multidistrict Litigation (JPMDL) heard a motion to create a new Eliquis multidistrict litigation in New York. Currently, this litigation is comprised of 34 related actions filed in 12 different federal districts. The Michael Brady Lynch firm is seeking justice for our clients who took
Read MoreDangers of Type 2 Diabetes Medication
Type 2 diabetes affects almost 10% of the American population and that number grows by nearly 2 million ever year. Unfortunately, many pharmaceutical companies see your diagnosis as a financial opportunity. Manufacturers rush drugs to market without rigorous testing just to cash in. This is the case with a popular Type 2 diabetes medication, Onglyza.
Read More
Science Supports Compulsive Behaviors in Abilify Users
It seems far-fetched. There is no way a side effect could do that. This is the sentiment for many friends and family members when they learn their loved one developed a compulsive behavior like excessive gambling while taking the prescription drug, Abilify. Unfortunately, it is true for thousands of Americans who took the drug, and
Read More
Invokana Lawsuit Update
There is a recent development in the Invokana lawsuit against the manufacturer, Janssen Pharmaceutical, a subsidiary of Johnson & Johnson. The company netted almost $1 billion in profits from Invokana in 2016 alone. The Judicial Panel on Multidistrict Litigation (JPMDL) issued an order to consolidate dozens of Invokana (canagliflozin) diabetic ketoacidosis (DKA) and kidney damage lawsuits to
Read More